by Elena Iemma | Oct 28, 2021 | Featured, Thinking Out Loud -Blog
First Class? (Class I) Are you working with mRNA, CAR-T, or gene/cell therapy? Then this is news that you can use! EpiVax has First Class HLA Class I prediction tools. Assessing the immunogenicity risk of “new modalities” includes CTL (Class I) epitopes, addition to...
by Elena Iemma | Aug 31, 2021 | Featured, Thinking Out Loud -Blog
From Disco to BTS Time flies when you are having fun! I totally missed the 10th anniversary of “Thinking Out Loud” a.k.a TOL – this newsletter. Do you want to see the first post? I hope you like disco! Lucky for you, I’ve moved on...
by Elena Iemma | Jul 28, 2021 | Featured, Thinking Out Loud -Blog
(Delta) Variants at the Gates Been to the Disco lately? In the Netherlands, dancing is fueling a new wave of COVID infections. You can’t ignore the rise of COVID-19 cases globally after the Delta variant began circulating widely in June. Our hearts go out to...
by Elena Iemma | Jul 6, 2021 | Featured, News
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and...
by Elena Iemma | Jun 14, 2021 | Featured, Thinking Out Loud -Blog
The Curious Case of HCP-driven Immunogenicity The FDA briefly “paused” the Johnson & Johnson adenovirus-based COVID-19 vaccine in April, and the AstraZeneca vaccine (also adenovirus-based) was in the news as early as March. Both of these pauses were to...